Sucampo Pharmaceuticals Inc. (SCMP) Downgraded to Buy at Vetr Inc.
Vetr lowered shares of Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) from a strong-buy rating to a buy rating in a report published on Monday morning. Vetr currently has $14.00 target price on the biopharmaceutical company’s stock.
A number of other research analysts have also recently commented on SCMP. Maxim Group reaffirmed a buy rating on shares of Sucampo Pharmaceuticals in a research report on Monday, July 11th. Mizuho reiterated a buy rating on shares of Sucampo Pharmaceuticals in a research note on Monday, July 11th. Roth Capital reiterated a buy rating on shares of Sucampo Pharmaceuticals in a research note on Tuesday, July 12th. Jefferies Group decreased their price objective on Sucampo Pharmaceuticals from $16.00 to $14.00 and set a hold rating on the stock in a research note on Thursday, August 4th. Finally, Zacks Investment Research upgraded Sucampo Pharmaceuticals from a sell rating to a hold rating in a research note on Monday, August 8th. Five equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company currently has a consensus rating of Buy and an average price target of $18.73.
Shares of Sucampo Pharmaceuticals (NASDAQ:SCMP) opened at 12.79 on Monday. The firm has a market capitalization of $547.54 million, a price-to-earnings ratio of 44.88 and a beta of 1.28. The stock’s 50 day moving average price is $11.73 and its 200-day moving average price is $11.38. Sucampo Pharmaceuticals has a 52 week low of $9.59 and a 52 week high of $26.96.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last issued its quarterly earnings results on Wednesday, August 3rd. The biopharmaceutical company reported $0.23 EPS for the quarter, beating analysts’ consensus estimates of $0.22 by $0.01. Sucampo Pharmaceuticals had a return on equity of 42.18% and a net margin of 6.65%. The firm had revenue of $52 million for the quarter, compared to analysts’ expectations of $48.33 million. During the same quarter in the prior year, the firm earned $0.21 EPS. The business’s revenue for the quarter was up 49.1% compared to the same quarter last year. Equities analysts predict that Sucampo Pharmaceuticals will post $1.03 earnings per share for the current year.
Several institutional investors have recently bought and sold shares of the company. Pacad Investment Ltd. purchased a new position in Sucampo Pharmaceuticals during the first quarter worth about $528,000. Teachers Advisors Inc. boosted its position in Sucampo Pharmaceuticals by 38.5% in the first quarter. Teachers Advisors Inc. now owns 423,391 shares of the biopharmaceutical company’s stock worth $4,628,000 after buying an additional 117,700 shares during the last quarter. Algert Global LLC boosted its position in Sucampo Pharmaceuticals by 33.9% in the first quarter. Algert Global LLC now owns 19,232 shares of the biopharmaceutical company’s stock worth $210,000 after buying an additional 4,872 shares during the last quarter. Mckinley Capital Management LLC Delaware boosted its position in Sucampo Pharmaceuticals by 147.7% in the first quarter. Mckinley Capital Management LLC Delaware now owns 232,824 shares of the biopharmaceutical company’s stock worth $2,545,000 after buying an additional 138,829 shares during the last quarter. Finally, BlackRock Fund Advisors boosted its position in Sucampo Pharmaceuticals by 3.1% in the first quarter. BlackRock Fund Advisors now owns 1,630,036 shares of the biopharmaceutical company’s stock worth $17,816,000 after buying an additional 48,420 shares during the last quarter. Hedge funds and other institutional investors own 40.64% of the company’s stock.
About Sucampo Pharmaceuticals
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on research and development of drugs to treat gastrointestinal, ophthalmic and oncology-based inflammatory disorders. It operates through development and commercialization of pharmaceutical products segment. Its operations are conducted through Sucampo AG, based in Zug, Switzerland, through which the Company conducts certain worldwide and European operations; Sucampo Pharma, LLC, based in Tokyo and Osaka, Japan and R-Tech Ueno, Ltd., based in Kobe, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, based in Rockville, Maryland, through which the Company conducts operations in North and South America, and Sucampo Pharma Europe, Ltd., based in Oxford, the United Kingdom.
Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.